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DESIGNER DRUGS
Deaths associated with new designer drug 5-IT
L Nitin Seetohul lecturer in forensic toxicology, Peter D Maskell lecturer in forensic toxicology,
Giorgia De Paoli lecturer in forensic toxicology, Derrick J Pounder professor of forensic medicine
Centre for Forensic and Legal Medicine, University of Dundee, Dundee DD1 4HN, UK
5-IT or 5-API is the common name for a newly emerging
designer drug.1 It is a positional isomer of the tryptamine drug
α-methyltryptamine and has the chemical structure
(1H-indol-5-yl)propan-2-amine. Currently not controlled in
Europe, it is covered, however, by the federal analogue acts in
the USA2 and Australia.3
Very little is known about the acute or chronic effects of 5-IT.
An oral dose of 20 milligrams is said to produce long lived
stimulant effects, including increased heart rate, anorexia,
diuresis, and slight hyperthermia for about 12 hours.4
Recently we identified 5-IT in postmortem blood samples of
two young adults. The substance was found in combination with
other drugs in one case. In the other, 5-APB/6-APB (a designer
drug similar in some respects to the chemical structure of
3,4-methylenedioxyamphetamine (MDA)) was also found. The
National Board of Forensic Medicine in Sweden has recently
identified the drug in 14 deaths and 5-IT was said to be the
direct cause of death in two of these cases.5
5-IT is inexpensive, easily available online as a so called
research chemical and therefore has the potential for becoming
a replacement for other recently banned designer drugs. The
medical community should be aware of both the availability
and use of 5-IT within the UK. The drug needs to be banned,
but again regulatory control in the UK will be chasing designer
drug innovation.
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